KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Invested Capital: 2018-2025

Historic Invested Capital for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $437.8 million.

  • Aurinia Pharmaceuticals' Invested Capital fell 6.63% to $437.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $437.8 million, marking a year-over-year decrease of 6.63%. This contributed to the annual value of $450.1 million for FY2024, which is 3.84% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Invested Capital is $437.8 million, which was up 6.59% from $410.8 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Invested Capital high stood at $485.7 million for Q2 2023, and its period low was $298.2 million during Q3 2021.
  • Moreover, its 3-year median value for Invested Capital was $443.4 million (2024), whereas its average is $445.0 million.
  • Its Invested Capital has fluctuated over the past 5 years, first decreased by 25.24% in 2021, then surged by 42.01% in 2022.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Invested Capital stood at $479.1 million in 2021, then fell by 15.37% to $405.4 million in 2022, then rose by 15.44% to $468.1 million in 2023, then fell by 3.84% to $450.1 million in 2024, then declined by 6.63% to $437.8 million in 2025.
  • Its Invested Capital was $437.8 million in Q3 2025, compared to $410.8 million in Q2 2025 and $421.5 million in Q1 2025.